BioNotebook: TPG's Aptalis files for $500 million IPO, Shire extends offer for ViroPharma
This article was originally published in Scrip
The days before and after Christmas weren’t completely devoid of news. A pair of companies announced plans for initial public offerings, including an IPO for private equity-backed Aptalis. An antibacterial drug developer raised $18 million in a private financing, while a company testing a multiple sclerosis therapy raised $8 million in a secondary offering. A small oncology specialist said it raised more than $3 million in an add-on offering. And Shire extended its tender offer for the $4.2 billion takeover of ViroPharma.